(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 6.02% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.
Ani Pharmaceuticals's revenue in 2024 is $517,460,000.On average, 4 Wall Street analysts forecast ANIP's revenue for 2024 to be $11,339,774,862, with the lowest ANIP revenue forecast at $11,283,211,994, and the highest ANIP revenue forecast at $11,389,332,910. On average, 4 Wall Street analysts forecast ANIP's revenue for 2025 to be $12,142,917,247, with the lowest ANIP revenue forecast at $11,872,120,159, and the highest ANIP revenue forecast at $12,291,780,144.
In 2026, ANIP is forecast to generate $12,929,973,715 in revenue, with the lowest revenue forecast at $12,813,366,542 and the highest revenue forecast at $13,162,349,159.